Journals / Gülhane Tıp Dergisi / 2008 / Cilt: 50 - Sayı: 4

Serum interleukin-13 (IL-13) levels in patients with fibromyalgia

Fibromiyaljili hastalarda serum interlökin-13 (IL-13) düzeyleri

Pages
257–260
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

In our particular experience serum IL-13 levels are low in patients with fibromyalgia, and this condition may be related to chronic subclinical inflammation.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Fibromyalgia is a disease characterized by widespread chronic pain and specific tender points on clinical examination.
📊
Key Findings & Data:The aim of this study was to determine serum interleukin-13 (IL-13) levels in patients with fibromyalgia.
💡
Conclusion & Impact:In our particular experience serum IL-13 levels are low in patients with fibromyalgia, and this condition may be related to chronic subclinical inflammation.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Fibromiyalji · İnterlökin-13 · Kadın

Abstract

Fibromyalgia is a disease characterized by widespread chronic pain and specific tender points on clinical examination. The pathogenesis of fibromyalgia is not known, however genetic predisposition, trauma, psychopathologic reasons, viral infections and immunological mechanisms are thought to play a possible role in the pathogenesis. The aim of this study was to determine serum interleukin-13 (IL-13) levels in patients with fibromyalgia. Twenty nine female patients with fibromyalgia and 26 healthy women were enrolled in the study. In order to exclude possible autoimmune and rheumatologic diseases, C-reactive protein, rheumatoid factor, antinuclear antibody, compleman, uric acid and thyroid hormone levels were determined, and complete blood count and urine analysis were performed. Serum IL-13 levels were measured by ELISA method. The mean age of the patients was 31.65±5.05 years, and the mean age of the control group was 29.38±4.11 years. The mean duration of the disease was 6.03±2.11 years. The mean number of tender fibromyalgia trigger points was 13.72±1.8. The mean serum IL-13 levels in the patient and control groups were 180.69±57 pg/ml and 254.13±82.25 pg/ml, respectively (p=0.001). In our particular experience serum IL-13 levels are low in patients with fibromyalgia, and this condition may be related to chronic subclinical inflammation.

Özet

Fibromiyalji yaygın kronik ağrı ve muayenede spesifik hassas noktalar ile karakterli bir hastalıktır. Fibromiyaljinin patogenezi bilinmemekte, ancak genetik yatkınlığın, travmanın, psikopatolojik nedenlerin, viral enfeksiyonların ve immünolojik mekanizmaların patogenezde rolü olabileceği düşünülmektedir. Bu çalışmanın amacı fibromiyaljili hastalarda serum interlökin-13 (IL- 13) düzeylerini tespit etmekti. Fibromiyalji tanısı almış 29 bayan hasta ve 26 sağlıklı bayan çalışmaya alındı. Olası otoimmün ve romatolojik hastalıkların dışlanması için C-reaktif protein, romatoid faktör, antinükleer antikor, kompleman, ürik asid ve tiroid hormon düzeyleri belirlendi, tam kan sayımı ve idrar tetkikleri yapıldı. Serum IL-13 düzeyleri ELISA yöntemi ile ölçüldü. Hastaların yaş ortalaması 31.65±5.05 yıl, kontrol grubunun yaş ortalaması ise 29.38±4.11 yıl idi. Ortalama hastalık süresi 6.03±2.11 yıldı. Hastaların hassas fibromiyalji tetik nokta sayıları ortalama 13.72±1.81 olarak bulundu. Hasta ve kontrol gruplarında ortalama serum IL-13 düzeyleri sırası ile 180.69±57 pg/ml ve 254.13±82.25 pg/ml olarak saptandı (p=0.001). Bu sonuçlara göre fibromiyaljili hastalarda serum IL-13 düzeyleri düşüktür ve bu durum kronik subklinik inflamasyonla ilişkili olabilir.

🔖

Cite This Article

KESKİN, G., İNAL, A., KESKİN, E. D., MUŞABAK, U., ŞENGÜL, A., KÖSE, K. (2008). Serum interleukin-13 (IL-13) levels in patients with fibromyalgia. Gülhane Tıp Dergisi, Cilt: 50 - Sayı: 4, 257–260. https://ajindex.com/articles/226354

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (15)

  1. Wallace DJ, Linker-Israeli M, Hallegua D, Silverman S, Silver D, Weisman MH. Cytokines play an aetiopathogenetic role in fibromyalgia: a hypothesis and pilot study. Rheumatology 2001; 40: 743-749
  2. Yunus MB, Khan MA, Rawlings KK, Green JR, Olson JM, Shah S. Genetic linkage analysis of multicase families with fibromyalgia syndrome. J Rheumatol 1999; 26: 408-412
  3. Culclasure TF, Enzenauer RJ, West SG. Post-traumatic stress disorder presenting as fibromyalgia syndrome. Am J Med 1993; 94: 548-549
  4. Weinberger LM. Traumatic fibromyositis: a critical review of an enigmatic concept. West J Med 1997; 127: 99-103
  5. Gur A, Karakoç M, Nas K, et al. Cytokines and depression in cases with fibromyalgia. J Rheumatol 2002; 29: 358-361
  6. Goldenberg DL. Fibromyalgia and its relation to chronic fatigue syndrome, viral illness and immune abnormalities. J Rheumatol Suppl 1989; 19: 91-93
  7. Gur A, Karakoc M, Erdogan S, Nas K, Cevik R, Sarac AJ. Regional blood flow and cytokines in young females with fibromyalgia. Clin Exp Rheumatol 2002; 20: 753-760
  8. Salemi S, Rethage J, Wollina U, et al. Detection of interleukin 1ß (IL-1ß), IL-6, and tumor necrosis factor- α in skin of patients with fibromyalgia. J Rheumatol 2003; 30: 146-150
  9. Su SY, Chen JJ, Lai CC, Chen CM, Tsai FJ. The association between fibromyalgia and polymorphism of monoamine oxidase A and interleukin-4. Clin Rheumatol 2007; 26: 12-16
  10. Uçeyler N, Valenza R, Stock M, Schedel R, Sprotte G, Sommer C. Reduced levels of antiinflammatory cytokines in patients with chronic widespread pain. Arthritis Rheum 2006; 54: 2656-2664
  11. Caro XJ. Is there an immunologic component to the fibrositis syndrome? Rheum Dis Clin North Am 1989; 15: 169-186
  12. Clauw DJ, Chrousos GP. Chronic pain and fatigue syndromes: overlapping clinical and neuroendocrine features and potential pathogenic mechanisms. Neuroimmunomodulation 1997; 4: 134-153
  13. Cohen H, Neumann L, Shore M, Amir M, Cassuto Y, Buskila D. Autonomic dysfunction in patients with fibromyalgia: application of power spectral analysis of heart rate variability. Semin Arthritis Rheum 2000; 29: 217-227
  14. Rowe PC, Bou Holaigah I, Kan JS, Calkins H. Is neurally mediated hypotension an unrecognized cause of chronic fatigue? Lancet 1995; 345: 623-624
  15. Torpy DJ, Papanicolaou DA, Lotsikas AJ, Wilder RL, Chrousos GP, Pillemer SR. Responses of the sympathetic nervous system and the hypothalamic-pituitary-adrenal axis to interleukin-6: a pilot study in fibromyal